Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Xiaolong Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3096-4981; OpenAlex author ID A5100393815. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2025: 3 papers

Papers 3

  1. Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models. Last author DOI 10.1002/advs.202407976↗
  2. The CD39-CD73-adenosine axis: Master regulator of immune evasion and therapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2025.189443↗
  3. FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system. Co-author DOI 10.1186/s12967-025-06304-w↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangeng Weng · 1 shared paper, 2025 · strength 0.30
  2. Qiangda Chen · 1 shared paper, 2025 · strength 0.30
  3. Shuping Wang · 1 shared paper, 2025 · strength 0.28
  4. Yulan Li · 1 shared paper, 2025 · strength 0.28
  5. Xueyan Zhang · 1 shared paper, 2025 · strength 0.28
  6. Haijun Yu · 1 shared paper, 2025 · strength 0.23
  7. Zhixiong Cai · 1 shared paper, 2025 · strength 0.23
  8. Xiaoling Yu · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.